Ubiquitin-proteasome system as a target for anticancer treatment-an update

Authors
Kim, Yeon JungLee, YeonjooShin, HyungkyungHwang, SuAPark, JinyoungSong, Eun Joo
Issue Date
2023-07
Publisher
대한약학회
Citation
Archives of Pharmacal Research, v.46, no.7, pp.573 - 597
Abstract
As the ubiquitin-proteasome system (UPS) regulates almost every biological process, the dysregulation or aberrant expression of the UPS components causes many pathological disorders, including cancers. To find a novel target for anticancer therapy, the UPS has been an active area of research since the FDA's first approval of a proteasome inhibitor bortezomib in 2003 for treating multiple myeloma (MM). Here, we summarize newly described UPS components, including E3 ubiquitin ligases, deubiquitinases (DUBs), and immunoproteasome, whose malfunction leads to tumorigenesis and whose inhibitors have been investigated in clinical trials as anticancer therapy since 2020. We explain the mechanism and effects of several inhibitors in depth to better comprehend the advantages of targeting UPS components for cancer treatment. In addition, we describe attempts to overcome resistance and limited efficacy of some launched proteasome inhibitors, as well as an emerging PROTAC-based tool targeting UPS components for anticancer therapy.
Keywords
MAINTENANCE THERAPY; MDM2 INHIBITOR; CANCER; DISCOVERY; POTENT; DEGRADATION; CARFILZOMIB; DISULFIRAM; PATHWAY; USP15; Ubiquitin-proteasome system (UPS); E3 ligase; Deubiquitinating enzymes (DUBs); Proteasome; Cancer; Small molecule inhibitors
ISSN
0253-6269
URI
https://pubs.kist.re.kr/handle/201004/113498
DOI
10.1007/s12272-023-01455-0
Appears in Collections:
KIST Article > 2023
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE